ObjectiveTo investigate the effect of EGFR-TKIs combined with radiotherapy on the immune function of patients with advanced non-small cell lung cancer, and observe the clinical efficacy. MethodsA total of 96 patients with advanced non-small cell lung cancer (NSCLC) in department of tumor surgery of our hospital from June 2012 to June 2015 were randomly divided into the experimental group(46 cases) and the control group (50 cases),and the control group were treated with radiotherapy and basic treatment, while the observation group recived EGFR-TKIs combined with radiotherapy on the base of basic treatment. The treatment effect, adverse reactions and changes in immune function. in the two groups were observed. ResultsThe total effective rate (52.17%) in the experimental group (52.17%) was significantly higher than that in the control group (30.00%,P＜0.05). Compared to before treatment, the levels of CD4+,CD4+/CD8+ and NK cells were significantly higher after treatment for one and four courses, while the level of CD8+ was significantly lower, the levels of CD4+,CD4+/CD8+ and NK cells in the experimental group were significantly higher than those in control group, and the level of CD8+ was significantly lower than that in control group(P＜0.05).The incidence of adverse reactions in the experimental group (6.52%) was significantly lower than that in the control group (24.00%, P=0.038). ConclusionsEGFR-TKIs combined with radiotherapy can improve the immune function of patients with advanced NSCLC, the clinical efficacy is remarkable, and it can reduce the incidence of adverse reactions.

无